Moreover, a study highlighted that EZH2 is upregulated in melanoma murine models upon treatment with anti-CTLA-4 and IL-2 immunotherapies, with subsequent repression of critical immune-related genes in tumor infiltrating lymphocytes such as PD-L1, T-cell immunoglobulin and mucin domain-3 (TIM-3), and lymphocyte activation gene-3 (LAG-3) [94]. The gene discussed is LAG3; the disease is melanoma.